<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN">
<html>
<head>
<meta content="text/html;charset=ISO-8859-1" http-equiv="Content-Type">
<title></title>
</head>
<body bgcolor="#ffffff" text="#000000">
The Avantguardian wrote:
<blockquote cite="mid20050908125011.39050.qmail@web60524.mail.yahoo.com"
type="cite">
<pre wrap="">
--- Gary Miller <a class="moz-txt-link-rfc2396E" href="mailto:aiguy@comcast.net"><aiguy@comcast.net></a> wrote:
</pre>
<blockquote type="cite">
<pre wrap="">
Actually a vaccine that prevents the disease in the
first place would be the
bigger money maker and result in the least risk of
the disease continuing
it's spread.
In that way you don't limit your customers to those
who already have the
disease but rather a much larger group of the
general population that would
have reason to fear accidently contracting the
disease.
More importantly the larger potential earnings
serves as a larger financial
incentive to the drug companies to perform research.
</pre>
</blockquote>
<pre wrap=""><!---->
You would think so wouldn't you? The truth, however,
from an insider's POV, is that nobody in the U.S. that
I am aware of is working on a prophylactic vaccine.
The vaccines which are out and being tested (none are
that impressive) are all therapeutic vaccines for use
with people who are already infected. There was a some
buzz a few years ago about european vaccine that used
an attenuated virus with a deleted nef gene, but
apparently it was still capable of causing AIDS. But
like I said, in the U.S., I am unaware of any at all.
Aside from the economic luddism I metioned, I am not
sure why this is the case. But another large factor
has to do with the technical challenge of testing it.
Apparently, the day that you can grab some kid at risk
of infection off the street and test your experimental
vaccine on him as Louis Pasteur did is long gone.
</pre>
</blockquote>
<br>
In my business we are going about our way to commercialize 2 main
nutraceutical ingredients.<br>
One has ethnobotanical history but no current usage in humans,
excluding myself and current consumers<br>
of a minor use food product containing it.<br>
The other cannabis has had a hiatus of usage since 1930 in North <br>
America. Some of its components are back in use but most are not.<br>
<br>
How does one get large scale use to warrant human consumption but at a
cost that is<br>
not one of 5-10 years of corporation subsidized trials? <br>
One goes to the animal nutrition/supplementation market and
commercializes it.<br>
<br>
Thousands of horses, dogs and cats populate North America. <br>
Wellness in animals creates an affinity market over time in their
owners.<br>
In the horse business there are lots of owners who sneak a scoop of
their<br>
animals meds because they see that these things are cheap , effective
and<br>
many times unavailable in the human market.<br>
<br>
After 5-10 years of this, a commercial market supported data package<br>
is ready to put to the herbal/natural health practitioner field.<br>
They utilize the loyalty and trust bond they have with customers to<br>
recommend things that may or may not be mainstream.<br>
<br>
So , you can get pretty close to the Louis Pasteur way.<br>
<br>
Of course the other way is to commercialize your wares in <br>
China or India where the marketplace is more willing to<br>
put novel science into full commercialization.<br>
ex- <a class="moz-txt-link-freetext" href="http://www.Sibiono.com">http://www.Sibiono.com</a> 's GMO adenovirus grown on stem cell tissue
cultures for cancer treatment.<br>
<br>
Yes , you must shun or pass by North America for its paternalistic
protectionist<br>
system which wants to provide total risk free lives. No risk=no change.<br>
<br>
Hyperbaric hydrogen cancer treatment was killed 30 years ago for that
very reason and noneother.<br>
<br>
Ethics say commercialize in North <br>
American humans first, reality is the disincentives law and economics<br>
make you say F**K it... its not worth the trouble.<br>
<br>
<br>
<br>
</body>
</html>